DAJY(SZ:002030)2022-12-08 08:46Group 1: Business Overview - The main revenue sources of the company include reagent income, instrument income, and service income, with PCR diagnostic reagents being the primary contributor to reagent income [2][3] - In 2014, the service revenue's operating cost increased by 88.04% compared to the previous year due to aggressive marketing efforts for independent laboratory services [3] - The company plans to enhance the profitability of independent laboratories rather than simply expanding the number of labs [3][4] Group 2: Financial Performance - In 2014, the revenue from PCR diagnostic reagents exceeded 500 million, accounting for approximately 80% of the reagent income, with an annual growth rate of around 20% [4] - The company's operating revenue grew by 27.13% in 2014, but net profit growth was significantly lower due to a substantial decrease in investment income compared to the previous year [4] Group 3: Future Growth and Strategy - The company is focusing on industry chain layout and is investing in specialized companies through equity participation [5] - The second-generation gene sequencing business is being developed through two subsidiaries, with one focusing on prenatal testing and the other providing testing services [4]